SCHEMBL20723212

SCHEMBL20723212

CNC(=O)c1cc(C(C)C)n2nc(C)c(-c3ccccc3)c2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 10/20 0.50
▸ MAPT P10636 10/20 0.50
▸ NPSR1 Q6W5P4 6/20 0.50
▸ MAPK1 P28482 3/20 0.50
▸ HSP90AA1 P07900 1/20 0.50
▸ ALDH1A1 P00352 5/20 0.47
▸ HPGD P15428 3/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ GAA P10253 1/20 0.46
▸ TDP1 Q9NUW8 3/20 0.46
▸ LMNA P02545 2/20 0.46
▸ HTT P42858 2/20 0.46
▸ GLA P06280 1/20 0.46
▸ ATM Q13315 1/20 0.46
▸ NPC1 O15118 1/20 0.45
▸ HCRTR1 O43613 1/20 0.45
▸ TP53 P04637 1/20 0.45
▸ RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20722928 0.88 KDM4E (0.51) KDM4EMAPTNPSR1MAPK1HSP90AA1
SCHEMBL20723197 0.87 GLA (0.47) KDM4EMAPTNPSR1MAPK1HSP90AA1
SCHEMBL20722880 0.86 KDM4E (0.52) KDM4EMAPTNPSR1MAPK1HSP90AA1
SCHEMBL20723228 0.84 KDM4E (0.48) KDM4EMAPTNPSR1MAPK1HSP90AA1
SCHEMBL20723257 0.82 NPSR1 (0.53) KDM4EMAPTNPSR1MAPK1HSP90AA1
SCHEMBL24923398 0.82 GLA (0.55) KDM4EMAPTNPSR1MAPK1HSP90AA1
SCHEMBL20723149 0.82 MAPT (0.54) KDM4EMAPTNPSR1MAPK1HSP90AA1
SCHEMBL20723082 0.81 GLA (0.48) KDM4EMAPTNPSR1MAPK1HSP90AA1
SCHEMBL20722905 0.80 MAPT (0.43) KDM4EMAPTNPSR1MAPK1HSP90AA1
SCHEMBL20722940 0.79 MAPT (0.43) KDM4EMAPTNPSR1MAPK1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230037225-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS APELIN RECEPTOR AGONISTS Sanford Burnham Prebys Medical Discovery Institute 2023-02-02 — — US disclosed
US-11345705-B2 Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists Sanford Burnham Prebys Medical Discovery Institute (US) 2022-05-31 — — US disclosed
US-20210040098-A1 APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF Sanford Burnham Prebys Medical Discovery Institute 2021-02-11 — — US disclosed
EP-3664806-A1 APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2020-06-17 — — EP disclosed
WO-2019032720-A1 APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2019-02-14 — — WO disclosed
WO-2019032720-A1 APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2019-02-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11345705-B2 Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists APLNR, AP3B1, AGTR1 KDM4E 4400/4885MAPT 3809/4885NPSR1 184/4885
US-20210040098-A1 APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF APLNR, APMAP, EDNRA KDM4E 4688/4885MAPT 4138/4885NPSR1 138/4885
US-20230037225-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS APELIN RECEPTOR AGONISTS APLNR, AP3B1, AGTR1 KDM4E 4400/4885MAPT 3809/4885NPSR1 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback